UBS Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)

June 16, 2026 9:27 AM

UBS analyst Michael Yee reiterated a Buy rating and $25.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found